The Nemours Foundation

The Nemours Foundation Nemours Biomedical Research - Delaware Division, doing business as Nemours Children's Hospital, Delaware, is a tax-exempt nonprofit research organization and subsidiary of Nemours Children's Clinic that serves as both a prime recipient and subrecipient on federal biomedical research grants, with no federal contract awards in the recent portfolio.

Nemours Delaware operates as a pediatric research and clinical institution headquartered in Wilmington, Delaware. The organization competes exclusively in the federal grant market under full-and-open competition; there are no set-aside designations in the source data. Recent grant activity spans 202 total awards (49% prime recipient, 51% sub-recipient) across 40 distinct federal agencies, with combined obligated dollars of $459.8 million against $116 thousand in combined potential value—a ratio reflecting the distinction between announced project ceilings and actual obligated funding across multi-year research grants.

The organization's customer concentration is driven by NIH grant programs. The top five agencies account for 55% of recent awards: the National Institute of General Medical Sciences (61 awards), Health Resources and Services Administration (17 awards), the National Institutes of Health Office of the Director (12 awards), the National Institute of Child Health and Human Development (12 awards), and the National Cancer Institute (10 awards). Dollar concentration aligns closely with award volume—NIGMS and HRSA dominate both dimensions. Secondary customers include the Substance Abuse and Mental Health Services Administration, the National Institute of Neurological Disorders and Stroke, the National Heart Lung and Blood Institute, and the Defense Health Agency.

Nemours Delaware's capability portfolio centers on pediatric biomedical and clinical research. Recent prime-recipient work includes a $593,363 SAMHSA award (FY 2026–2031) under the Center for Mental Health Services Projects of Regional and National Significance program (CFDA 93.532) to develop and disseminate evidence-based trauma-informed care interventions through the Center for Pediatric Traumatic Stress, with clinical implementation sites across seven states. A $763,505 National Institute of Diabetes and Digestive and Kidney Diseases research grant (FY 2026–2031, CFDA 93.847) funds a multisite randomized controlled trial of TYPE 1 TOGETHER, a peer mentoring intervention to improve continuous glucose monitoring adherence in adolescents with Type 1 Diabetes across Nemours Delaware (Wilmington), Nemours Orlando, and University of Tennessee Memphis. A $1.14 million National Institute of General Medical Sciences award (FY 2026–2031, CFDA 93.859) funds Phase 3 of the Delaware Comprehensive Sickle Cell Research Center (DE SCD COBRE), supporting biomedical research center infrastructure, investigator mentoring, and clinical research cores focused on sickle cell disease. Additional prime awards include research on precision neurostimulation for cognitive restoration ($1,074,636, NIH Office of the Director, FY 2025–2030), Down Syndrome-associated myeloid leukemia therapy targets (National Cancer Institute), plexiform neurofibroma biomarkers (Defense Health Agency, $548,659, FY 2025–2028), and shared decision-making interventions for adolescents with sickle cell disease (National Institute of Nursing Research, $789,558, FY 2026–2031).

As a subrecipient, Nemours Delaware participates in multi-site clinical trials and research networks. Named prime grantees include the University of Delaware (Delaware INBRE, Delaware Clinical and Translational Research [DE-CTR], ACCEL Clinical and Translational Research program), the Children's Hospital of Philadelphia (pediatric sepsis trials including PRoMPT BOLUS and FAST BOLUS, cardiac surgery outcomes research, pediatric primary hypertension screening implementation), the University of Kansas Medical Center Research Institute (Type 1 Together multisite trial coordination, pediatric nutrition research [NOURISH]), Columbia University (pediatric acute pain management trial), Drexel University (early intervention for autism diagnosis), and Emory University (sickle cell disease treatment studies). Nemours also subs to ICF Incorporated on Head Start training and technical assistance contracts.

Activity has grown modestly from 7 awards in 2022 to a peak of 27 in 2023, with subsequent years tracking at 21–24 awards annually. Fourteen awards (ultimate completion date within the next twenty-four months) face recompete, representing renewal cycles on established grant programs.

Service Contract Inventory data reflect minimal SCI-reportable activity: two subcontractor records spanning FY2024–FY2025 with 0.2 FTEs in FY2024 and 0.6 FTEs in FY2025. SCI captures only federal service contracts above the $150,000 threshold and excludes research grants; these figures do not represent the organization's total federal research workforce or revenue.